CA2500895A1 - Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose - Google Patents

Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose Download PDF

Info

Publication number
CA2500895A1
CA2500895A1 CA002500895A CA2500895A CA2500895A1 CA 2500895 A1 CA2500895 A1 CA 2500895A1 CA 002500895 A CA002500895 A CA 002500895A CA 2500895 A CA2500895 A CA 2500895A CA 2500895 A1 CA2500895 A1 CA 2500895A1
Authority
CA
Canada
Prior art keywords
seq
antibody
region
variable light
variable heavy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002500895A
Other languages
English (en)
Inventor
Jan Nilsson
Roland Carlsson
Jenny Bengtsson
Leif Strandberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinvent International AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0202959A external-priority patent/SE0202959D0/xx
Priority claimed from SE0302312A external-priority patent/SE0302312D0/xx
Application filed by Individual filed Critical Individual
Publication of CA2500895A1 publication Critical patent/CA2500895A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Abstract

La présente invention concerne l'immunisation passive pour le traitement ou la prévention de l'athérosclérose, reposant sur l'utilisation d'un anticorps humain isolé dirigé contre au moins un fragment oxydé d'apolipoprotéine B dans la fabrication d'une composition pharmaceutique pour le traitement thérapeutique ou prophylactique de l'athérosclérose à l'aide de l'immunisation passive. Elle concerne également une méthode de préparation de ces anticorps et un procédé de traitement d'un mammifère, de préférence un être humain, à l'aide d'un anticorps susmentionné pour conférer une immunisation passive.
CA002500895A 2002-10-04 2003-10-06 Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose Abandoned CA2500895A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SE0202959A SE0202959D0 (sv) 2002-10-04 2002-10-04 Peptide-Base passive immunization therapy for treatment of atherosclerosis
SE0202959-3 2002-10-04
SE0302312A SE0302312D0 (sv) 2002-10-04 2003-08-27 Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312-4 2003-08-27
PCT/SE2003/001469 WO2004030698A1 (fr) 2002-10-04 2003-09-22 Therapie par immunisation passive a base de peptides, pour traiter l'atherosclerose
SEPCT/SE03/01469 2003-09-22
PCT/SE2003/001547 WO2004030607A2 (fr) 2002-10-04 2003-10-06 Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose

Publications (1)

Publication Number Publication Date
CA2500895A1 true CA2500895A1 (fr) 2004-04-15

Family

ID=32074178

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002500895A Abandoned CA2500895A1 (fr) 2002-10-04 2003-10-06 Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose

Country Status (3)

Country Link
AU (1) AU2003267905B2 (fr)
CA (1) CA2500895A1 (fr)
WO (1) WO2004030607A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
RU2332986C2 (ru) 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
WO2008104194A1 (fr) * 2007-02-28 2008-09-04 Bioinvent International Ab Lipoprotéines de basse densité oxyde et leurs anticorps pour le traitement de plaques d'athérosclérose
WO2010005389A1 (fr) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Protéines conjuguées ou fusionnées à un anticorps spécifique des protéines ldl oxydées
EP2352521B1 (fr) 2008-10-14 2020-09-16 Genentech, Inc. Variants d'immunoglobuline et leurs utilisations
CA2754528A1 (fr) * 2009-03-06 2010-09-10 Genetech, Inc. Formulation d'anticorps
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5196324A (en) * 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
WO1994000592A1 (fr) * 1992-06-26 1994-01-06 Exocell, Inc. Anticorps monoclonaux agissant contre des lipoproteines glycatees de faible densite
KR0185334B1 (ko) * 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6225070B1 (en) * 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
AU773370B2 (en) * 1999-10-26 2004-05-20 Regents Of The University Of California, The Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
DE60103137T2 (de) * 2000-03-03 2005-05-25 Glaxosmithkline Biologicals S.A. Impstoff zur behandlung von atherosclerosis
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid

Also Published As

Publication number Publication date
AU2003267905B2 (en) 2009-02-05
AU2003267905A1 (en) 2004-04-23
WO2004030607A3 (fr) 2004-06-24
WO2004030607A2 (fr) 2004-04-15

Similar Documents

Publication Publication Date Title
US7601353B2 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
JP4716350B2 (ja) 潜伏期膜タンパク質に対する抗体およびそれらの使用
CA2517054C (fr) Utilisation d'acides nucleiques codant des molecules de type anticorps pour un traitement medical
JPH05507197A (ja) 結合部位を含む可溶性ペプチド類縁体
TW201922784A (zh) ４﹘１ｂｂ抗體及其製備方法和應用
RU2454428C2 (ru) Иммунотерапевтическое лечение
CA3032783C (fr) Anticorps de mort cellulaire programmee (pd-1) et son utilisation
US8008448B2 (en) Cotinine neutralizing antibody
JP2006506450A5 (fr)
AU2003267905B2 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2020108636A1 (fr) Anticorps anti-gitr complètement humanisé et son procédé de préparation
JP2021526013A (ja) 抗ヒトｌａｇ−３モノクローナル抗体とその応用
WO2008050907A1 (fr) Anticorps dirigé contre rgd dans une séquence d'acides aminés d'une protéine de matrice extracellulaire et procédé de fabrication et utilisation de celui-ci
AU2016202118A1 (en) Carrier immunoglobulins and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131009

FZDE Discontinued

Effective date: 20131009